Latest News and Press Releases

NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement

TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025...

NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

DOVER, DE, Dec. 13, 2024 (GLOBE NEWSWIRE) --  Pacific Green Technologies, Inc. ("Pacific Green"), (OTCQB: PGTK) announces that it has amended some material accounting policies following extensive...

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of...

TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update